FibroBiologics’ (FBLG) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of FibroBiologics (NASDAQ:FBLG) in a report issued on Tuesday,Benzinga reports. D. Boral Capital currently has a $16.00 target price on the stock.

Separately, HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of FibroBiologics in a research note on Tuesday, April 1st. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $13.00.

FibroBiologics Stock Performance

Shares of NASDAQ FBLG opened at $0.72 on Tuesday. The firm has a market cap of $27.47 million, a P/E ratio of -3.42 and a beta of -0.80. The stock has a fifty day moving average price of $0.94 and a two-hundred day moving average price of $1.35. FibroBiologics has a 1 year low of $0.70 and a 1 year high of $6.70.

FibroBiologics (NASDAQ:FBLG) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.04). On average, research analysts predict that FibroBiologics will post -0.53 earnings per share for the current fiscal year.

Institutional Trading of FibroBiologics

Hedge funds have recently modified their holdings of the business. Intech Investment Management LLC purchased a new stake in shares of FibroBiologics in the fourth quarter valued at $25,000. Virtu Financial LLC purchased a new stake in shares of FibroBiologics in the fourth quarter valued at $30,000. Raymond James Financial Inc. purchased a new stake in shares of FibroBiologics in the fourth quarter valued at $37,000. AQR Capital Management LLC purchased a new stake in shares of FibroBiologics in the first quarter valued at $29,000. Finally, Nuveen LLC purchased a new stake in shares of FibroBiologics in the first quarter valued at $31,000.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.